COMMUNIQUÉS West-GlobeNewswire

Ontario Shores partners with community organizations to bring dementia care training to families
17/06/2026
Whitby, Ontario, June 17, 2026 (GLOBE NEWSWIRE) -- Ontario Shores Centre for Mental Health Sciences (Ontario Shores) announced today that it is partnering with the Alzheimer Society of Durham Region to expand access to [...]
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
17/06/2026
First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment i More than 3 million cases of cUTIs are treated annually in [...]
AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042
17/06/2026
PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2042 THIS POSITIVE DECISION FROM THE USA [...]
Applied Biologics Announces Completion of Planned Enrollment Activities in the CAMPX Randomized Controlled Trial Evaluating XWRAP®
17/06/2026
SCOTTSDALE, Ariz., June 17, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
Compte-rendu de l’assemblée générale de TME Pharma
17/06/2026
Compte-rendu de l’assemblée générale de TME Pharma Berlin, Allemagne, le 17 juin 2026, 18 h 30 CET – TME Pharma N.V. (Euronext Growth Paris : ALTME), une société de biotechnologie en phase clinique spécialisée dans le [...]
Minutes of the TME Pharma Annual General Meeting
17/06/2026
Minutes of the TME Pharma Annual General Meeting Berlin, Germany, June 17, 2026, 6:30 p.m. CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of [...]
Eurobio Scientific: ERRATUM : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
17/06/2026
ERRATUM : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Paris, le 17 juin 2026 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro pour la [...]
RESTEM to Present at BIO International Convention
17/06/2026
MIAMI, June 17, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that CEO, [...]
Le brevet d’AB Science concernant le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant a été officiellement délivré aux Etats-Unis avec une durée de protection jusqu’en 2042
17/06/2026
COMMUNIQUÉ DE PRESSE LE BREVET D’AB SCIENCE CONCERNANT LE MASITINIB DANS LE TRAITEMENT DU CANCER DE LA PROSTATE MÉTASTATIQUE HORMONO-RÉSISTANT A ÉTÉ OFFICIELLEMENT DÉLIVRÉ AUX ÉTATS-UNIS AVEC UNE DURÉE DE PROTECTION [...]
TOMI Advances Toward NSF Certification to Address Multi-Billion-Dollar Pharmaceutical, Biotech and Cleanroom Decontamination Markets
17/06/2026
Certification process could position SteraMist® as a validated decontamination standard across biosafety cabinets, containment enclosures, cleanrooms, and life sciences facilities worldwide FREDERICK, Md., June 17, 2026 [...]
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
17/06/2026
Company expects to report topline 12-month clinical results in the second half of 2027 BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (Avalyn or the Company), a clinical-stage [...]
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
17/06/2026
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027 CAMBRIDGE, Mass [...]
Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data
17/06/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE [...]
Oncotelic Advances AI-Powered GMP Manufacturing Services Platform for Revenue-Generating AI and Robotics Manufacturing Services
17/06/2026
SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB: OTLC) today announced the completion of key Phase 2 objectives in its joint manufacturing automation [...]
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
17/06/2026
Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Precision Neuroscience™ Wins 2026 Webby Award; Earns Back-to-Back Fast Company World Changing Ideas Honor
17/06/2026
Both recognitions cite the Layer 7 cortical interface and its potential to restore independence for people living with paralysis NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision [...]
electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
17/06/2026
ROCKAWAY, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will participate in the iAccess Alpha Virtual [...]
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
17/06/2026
100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy Complete [...]
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
17/06/2026
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients [...]

Pages